2017
Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.
Wright N, Rida P, Krishnamurti U, Li X, Aneja R. Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity. Frontiers In Bioscience-Landmark 2017, 22: 193-211. PMID: 27814611, DOI: 10.2741/4481.Peer-Reviewed Original ResearchConceptsEthnic disparitiesAfrican AmericansAggressive breast cancer subtypeUnique tumor biologyBreast cancer subtypesPrecision medicine toolsDiagnostic assaysIndividualized cancer treatmentRacial health disparitiesClinical outcomesDevelopment of drugsPatient populationAncestry-associated differencesEfficacy biomarkersTargeted drugsHigh recurrenceMortality rateCentrosomal aberrationsBreast tumorsTumor biologyCancer subtypesHealth disparitiesMedicine toolsCancer treatmentPersonalized oncology
2016
Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid M, O’Regan R, Aneja R. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal Of Clinical Pathology 2016, 145: 871-878. PMID: 27298399, DOI: 10.1093/ajcp/aqw045.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoadjuvant chemotherapyEstrogen receptorComplete responseLuminal subtypeProgesterone receptorBreast cancerTriple-negative breast cancer subtypeNottingham grade 3Stromal lymphocytic infiltrationNegative breast cancer subtypeBreast cancer patientsBreast cancer subtypesHigh mitotic countPR negativityHER2 positivityOverall cohortLymphocytic infiltrationTNBC subtypesCancer patientsHER2 statusPathologic parametersKi67 indexNuclear gradeClinical data